# US 2008/0287288 A1 · Mesoporous Nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287288 A1
- Document ID: US20080287288A1
- Status: Published application
- Kind: A1
- Application number: 11/631,642
- Filed: 2005-07-05
- Published: 2008-11-20
- Earliest claimed: 2004-07-06
- Inventors: Jackie Y. Ying; Yu Han
- Web page: https://patentgrep.com/patent/US20080287288A1

## CPC

- C01B 37/02: Crystalline silica-polymorphs, e.g. silicalites {dealuminated aluminosilicate zeolites}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/12: Antihypertensives
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- B82Y 10/00: Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- C01B 37/00: Compounds having molecular sieve properties but not having base-exchange properties
- B01J 21/08: Silica
- B01J 29/0308: {Mesoporous materials not having base exchange properties, e.g. Si-MCM-41}
- B01J 35/647: {2-50 nm}
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides a process for making mesoporous nanoparticles. The process comprises providing an acidic mixture comprising a fluorocarbon surfactant, a second surfactant and a silica precursor. The silica precursor is then reacted to form the mesoporous nanoparticles.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A process for making mesoporous nanoparticles comprising:
providing an acidic mixture comprising a fluorocarbon surfactant, a second surfactant and a silica precursor; and
reacting the silica precursor to form the mesoporous nanoparticles.

### Claim 33 (depends on 32)

The process of claim 32 wherein the acidic mixture is an aqueous mixture.

### Claim 34 (depends on 32)

The process of claim 32 wherein the acidic mixture has a pH between about 0.5 and about 5

### Claim 35 (depends on 32)

The process of claim 32 wherein the fluorocarbon surfactant is cationic.

### Claim 36 (depends on 32)

The process of claim 32 wherein the second surfactant is an alkylene oxide block copolymer surfactant.

### Claim 37 (depends on 32)

The process of claim 32 wherein the silica precursor comprises a hydrolysable silane.

### Claim 38 (depends on 1)

The process of claim 1 wherein the acidic mixture also comprises a hydrophobic material.

### Claim 39 (depends on 7)

The process of claim 7 wherein the hydrophobic material is added before the silica precursor.

### Claim 40 (depends on 32)

The process of claim 32 wherein the step of preparing the acidic mixture comprises combining the silica precursor with an acidic surfactant mixture.

### Claim 41 (depends on 40)

The process of claim 40 wherein the ratio of silica precursor to acidic surfactant mixture is between about 1:100 and about 1:2 on a w/w, v/v or w/v basis.

### Claim 42 (depends on 32)

The process of claim 32 wherein the step of reacting the silica precursor comprises at least one of hydrolysing the silica precursor and condensing the silica precursor to form the mesoporous nanoparticles.

### Claim 43 (depends on 32)

The process of claim 32 wherein the step of reacting the silica precursor comprises steps of:
agitating the acidic mixture for sufficient time and at a sufficient temperature for at least partial hydrolysis of the silica precursor to form a hydrolysate; and
maintaining the mixture, or emulsion, at a temperature and for a time sufficient for reaction of at least one of the silica precursor and the hydrolysate to form the nanoparticles.

### Claim 44 (depends on 43)

The process of claim 43 wherein the step of agitating is conducted between about 10 and about 80° C. for between about 5 and about 50 hours.

### Claim 45 (depends on 43)

The process of claim 43 wherein the step of maintaining the mixture is conducted at between about 70 and about 150° C. for between about 10 and 100 hours.

### Claim 46 (depends on 32)

The process of claim 32 additionally comprising at least partially separating the nanoparticles from a fluid in which they are located.

### Claim 47 (depends on 46)

The process of claim 46 additionally comprising washing the nanoparticles with a washing liquid.

### Claim 48 (depends on 46)

The process of claim 46 also comprise heating the nanoparticles to between about 500 and about 1000° C. for between about 1 and about 20 hours.

### Claim 49 (depends on 32)

Mesoporous nanoparticles when made by the process of claim 32.

### Claim 50

A mesoporous nanoparticle having a particle size between about 1 and about 500 nm and a mean pore size between about 1 and about 50 nm, said nanoparticle being made by a process comprising providing an acidic mixture comprising a fluorocarbon surfactant, a second surfactant and a silica precursor, and reacting the silica precursor to form the mesoporous nanoparticles.

### Claim 51 (depends on 50)

The mesoporous nanoparticle of claim 50 wherein the pore size is between about 10 and about 50 nm.

### Claim 52

A mesoporous nanoparticle having a particle size between about 32 and about 500 nm and having a mesostructure selected from the group consisting of 3-D cubic, 3-D foam-like, 2-D hexagonal and wormlike, said nanoparticle being made by a process comprising providing an acidic mixture comprising a fluorocarbon surfactant, a second surfactant and a silica precursor, and reacting the silica precursor to form the mesoporous nanoparticles.

### Claim 53 (depends on 52)

The mesoporous nanoparticle of claim 52 wherein the pore size is greater than about 10 nm.

### Claim 54 (depends on 49)

Use of a mesoporous nanoparticle according to claim 49, or a plurality thereof, for an application selected from the group consisting of catalysis, gas adsorption, synthesis of quantum dots and magnetic nanoparticles in functional materials and bioimaging applications, and as carriers for drugs, genes and proteins for biomedical applications.

### Claim 55 (depends on 49)

A mesoporous nanoparticle according to claim 49, or a plurality thereof, when used in an application selected from the group consisting of catalysis, gas adsorption, synthesis of quantum dots and magnetic nanoparticles in functional materials and bioimaging applications, and as carriers for drugs, genes and proteins for biomedical applications.

### Claim 56 (depends on 49)

A catalyst comprising a mesoporous nanoparticle according to claim 49, or a plurality thereof, said nanoparticle(s) having a catalytic species associated therewith.

### Claim 57 (depends on 56)

The catalyst of claim 56 wherein the catalytic species is an enzyme.

### Claim 58 (depends on 56)

A method for catalysing a reaction comprising exposing a starting material to a catalyst according to claim 56, whereby the catalytic species of the catalyst is capable of catalysing the reaction of the starting material to a product.

### Claim 59 (depends on 56)

A method for producing a product comprising exposing a starting material to a catalyst according to claim 56, whereby the catalytic species of the catalyst is capable of catalysing a reaction of the starting material to the product.

### Claim 60 (depends on 59)

A product when made by the process of claim 59.

### Claim 61 (depends on 49)

A nanoparticle according to claim 49, said nanoparticle having a species selected from the group consisting of a drug, a gene and a protein associated therewith.

### Claim 62 (depends on 61)

Use of a nanoparticle according to claim 61 for the manufacture of a medicament for the treatment of a condition selected from the group consisting of cancer, AIDS, arthritis, diabetes, hormonal disfunction, hypertension and pain.

### Claim 63 (depends on 50)

A mesoporous nanoparticle according to claim 50, or a plurality thereof, when used in an application selected from the group consisting of catalysis, gas adsorption, synthesis of quantum dots and magnetic nanoparticles in functional materials and bioimaging applications, and as carriers for drugs, genes and proteins for biomedical applications.

### Claim 64 (depends on 50)

A catalyst comprising a mesoporous nanoparticle according to claim 50, or a plurality thereof, said nanoparticle(s) having a catalytic species associated therewith.

### Claim 65 (depends on 52)

A mesoporous nanoparticle according to claim 52, or a plurality thereof, when used in an application selected from the group consisting of catalysis, gas adsorption, synthesis of quantum dots and magnetic nanoparticles in functional materials and bioimaging applications, and as carriers for drugs, genes and proteins for biomedical applications.

### Claim 66 (depends on 52)

A catalyst comprising a mesoporous nanoparticle according to claim 52, or a plurality thereof, said nanoparticle(s) having a catalytic species associated therewith.

### Claim 67 (depends on 50)

A nanoparticle according to claim 50, said nanoparticle having a species selected from the group consisting of a drug, a gene and a protein associated therewith.

### Claim 68 (depends on 52)

A nanoparticle according to claim 52, said nanoparticle having a species selected from the group consisting of a drug, a gene and a protein associated therewith.

### Claim 69 (depends on 50)

Use of a mesoporous nanoparticle according to claim 50, or a plurality thereof, for an application selected from the group consisting of catalysis, gas adsorption, synthesis of quantum dots and magnetic nanoparticles in functional materials and bioimaging applications, and as carriers for drugs, genes and proteins for biomedical applications.

### Claim 70 (depends on 52)

Use of a mesoporous nanoparticle according to claim 52, or a plurality thereof, for an application selected from the group consisting of catalysis, gas adsorption, synthesis of quantum dots and magnetic nanoparticles in functional materials and bioimaging applications, and as carriers for drugs, genes and proteins for biomedical applications.
